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The ability to control wound contraction is important in 
preventing disfiguring scarring in burn and trauma patients. 
Fibroblasts within the wound generate the mechanical forces 
that cause this contraction, and their interactions with 
various extracellular matrix components are thought to reg-
ulate this process. Because pentoxifylline and the interferons 
are believed to moderate fibroblast production of such matrix 
components, we assessed the effects of these agents on wound 
contraction in vitro, using a model wherein dermal fibroblasts 
are incorporated into a collagen lattice. Pentoxifylline and 
F ibroblast-populated collagen lattices (FPCLs). model der-mal fibroblast function in a more in vivo-like environ-ment than do monolayer cultures [1]. This system en-ables fibroblasts to acquire an in vivo-like morphology not observed in monolayers [2,3]. The slower prolifera-
tive and metabolic rates of fibroblasts in collagen lattices also more 
closely resemble in vivo fibroblast function than do the relatively 
rapid rates of proliferation and metabolism seen in fibroblasts grown 
in monolayers [4]. Additionally, the response of fibroblasts to cyto-
kines is different in collagen lattices than in monolayer cultures 
[5,6] . Once embedded in the collagen lattice. fibroblasts reorganize 
and compact the collagen fibers. resulting in the contraction of the 
floating lattice. It is felt that this lattice contraction models wound 
contraction in vivo [4]. 
The ability to mimic wound contraction has made the FPCL a 
useful model for studying the basic biologic mechanisms involved 
in wound contraction and for testing the potential of various drugs 
to modulate this event [4,6-11] . Although wound contraction is a 
normal event in wound healing, excessive contraction resulting in 
disfiguring scarring occurs frequently with burn wounds [12,13] 
and can occur following plastic and reconstructive surgery [14,15] 
and skin grafting [16]. Identifying agents that have the potential to 
modulate wound contraction offers the opportunity to develop pre-
ventive treatments for affected patients. 
Although the actual mechanism by which fibroblasts contract 
collagen lattices is still the subject of debate, it has been shown that 
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interferon-a, -{3, and -y inhibited lattice contraction in a 
dose-dependent manner and showed no effect on cell number 
or cell viability. These results suggest that pentoxifylline and 
the interferons may retard wound contraction in vivo and thus 
reduce scarring associated with severely contracted wounds. 
Further study is needed to determine the mechanism of ac-
tion of these agents on the collagen lattice model. Key words: 
collagen lattice/wound healillg/perttoxifylline/interferon/dermal 
equivalent. ] 1ntlest Dermatol 102: 118 -121, 1994 
glycosaminoglycans [17,18], cellular fibronectin [19], andp1 inte-
grin collagen receptors [20,21] all playa role in FPCL contraction. 
For this reason. pharmacologic agents that alter the synthesis of these 
extracellular matrix components might also affect FPCL contrac-
tion. Pentoxifylline, a hemorrheologic agent capable of decreasing 
blood viscosity [22], has been used effectively to treat various skin 
disorders [23]. Previous studies show that pentoxifylline, as well as 
the interferons. differentially modulate dermal fibroblast produc-
tion of extracellular matrix components (including collagen, colla-
genase, fibronectin, and glycosaminoglycans) in an antifibrotic 
manner [5,24]. These studies suggest that pentoxifylline and the 
interferons may prevent scarring caused by excessive fibrosis . W e 
evaluated these agents in the FPCL model to determine if they may 
also prevent scarring caused by excessive wound contraction. 
MATERIALS AND METHODS 
Pentoxifylline and Interferons Pentoxifylline was a gift from 
Hoechst-Roussel. Somerville. NJ. Interferon alpha-2b recombinant (Intron 
A; specific activity. 2 X 108 U/mg protein) was a gift from Schering. Kenil-
worth, NJ. Human recombinant interferon-beta",,? (3.2 X 10? U/mg) was 
kindly provided by Berlex Laboratories. Inc .• Richmond, CA. Recombinant 
human interferon gamma-lb (3.2 X 10? U/mg) was generously supplied by 
Genentech. South San FranCISco, CA. These agents were stored according to 
manufacturer's suggestions. 
Cell Cultures Two fibroblast strains were isolated from human neonatal 
foreskins obtained from routine circumcision. as previously described [25]. 
and were used between passages 3 and 7. Stock cultures were maintained as 
monolayers in plastic culture dishes, using Dulbecco's modified Eagle's me-
dium (DMEM) (Gibco, Grand Island, NY), 1 % penicillin/streptomycin. 
and 10% calf serum (Hyclone, Logan, Utah). The cultures were incubated at 
37 °C in a humidified atmosphere of 5% CO2 , 
Lattice Cultures A solution of bovine collagen types I and III (3 mg 
collagen/ml; Vitrogen 100. Collagen Corp., Palo Alto. CAl was mixed with 
triple-strength DMEM, DMEM containing 20 mM Hepes buffer (Gibco. 
Grand Island. NY) to maintain neutral pH. calf serum. cel ls (detached by 
trypsin from monolayer confluent cultures). and appropriate drug dilutions. 
The solution was kept cold to prevent premature gelation. The final solution 
contained. by volume, 30% Vitrogen, 15% 3 X DMEM. 45% DMEM with 
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Hepes buffer, 10% calf serum, 4 X 10' cells/ml, and appropriate drug con-
centration. The lattices were cast, with 2 ml of the final solution per dish, in 
35-mm bacteriologic dishes (Falcon Labware, Oxnard, CAl, which fibro-
blasts adhere poorly to . The mixture ge lled within 10 min upon incubation 
at 37"C in 95% air, 5% CO2 , To assure even contraction, lattices were 
detached from the sides of the dishes approximately 2 h after gelation by 
rimming the edges of the dishes with sharp, sterile tweezers and gently 
shaking the dishes until the gels slid free ly. Lattice retraction was measured 
every day by placing the dishes over a flat ru ler on a black background and 
averaging the major and minor axes. After maximal retraction (3 - 4 d), 
lattices were digested with 4 mg/ml collagenase (Worthington Biochemi-
cal, Freehold , N]) for assessment of cell viabiliry by trypan blue excl usion. 
Statistical analysis to assess significance of data was performed using the 
two-tai led Srudcnt t test in the Statview 512 computer program. Signifi-
cance was ascribed to p values of 0.05 or less. 
RESULTS 
Two different fibroblast strains were studied, and each yielded par-
alle l results. For simplicity, th e results obtained with only one strain 
are presented. 
Cell and Serum Concentration FPCL contraction is depen-
dent on cell concentration (Fig 1a) as wel l as serum concentration 
(Fig 1b). Cell and serum concentrations of 4 X 104 cells/ml and 
10%, respectively, were found to be the optimal cond itions for 
studying agents that inhibit lattice contraction. 
Pentoxifylline Pentoxifylline inhibits lattice contraction in a 
dose-dependent manner (Fig 2). Significant differences between the 
control and the two highest drug concentrations (0.5 mg/ml and 1 
mg/ml) are apparent by the first day (p < 0.001). By day two, 
significant differences are seen between all doses. At the 1 mg/ml 
dose, contraction is almost completely blocked. 
Interferon-a Incorporation of IFN -a in the collagen lattice also 
results in a dose-dependent inhibition of lattice contraction (Fig 3), 
though to a lesser extent than that seen with pentoxifylline and 
IFN-fJ (Fig 4). Each day significant differences are seen between the 
control and all doses (p < 0.05). 
IFN-fJ IFN-fJ also inhibits lattice contraction in a dose-dependent 
manner and almost completely prevents contraction at 1 X 105 
U /ml (Fig 4) . On day one, the lattice diameters of the control and 
doses of 1 X 102 U /ml or higher are significantly different (p < 
0.05). On day two, differences between the control and doses of 
1 X 103 U/ml or higher are significant (p < 0.02). Significant dif-
ferences between the doses and the control on day three are seen 
with doses of 1 X 103 U/ml and higher (p < 0.02). 
IFN-y IFN-y also causes a dose-dependent inhibition of lattice 
contraction (Fig 5). The differences between the control and the 
doses become significant on day 2 (p < 0.02). On day 3, the diame-
ters of the doses are all significantly greater than the control, and 
p < 0.D1. 
Cell Proliferation and Viability For all four pharmacologic 
agents, no significant differences in cell number or viability be-
tween the control and treated cells are observed at the end of each 
experiment (data not shown). Thus, the dose-dependent inhibition 
of lattice contraction caused by pentoxifylline and the interferons 
cannot be due to cytotoxicity or inhibition of proliferation. 
DISCUSSION 
The purpose of this study was to determine whether pentoxifylline 
and the interferons cou ld inhibit the contraction of fibroblast popu-
lated collagen lattices, an ill vitro system that models wound con-
traction. Our results demonstrate that pentoxifylline and the inter-
ferons inhibit FPCL contraction in a dose-dependent manner. 
These findings suggest that these agents may be clinically useful for 
preventing scarring caused by severely contracting wounds, such as 
those wounds often found with burn and trauma patients. However, 
further studies using adult fibroblasts could strengthen the applica-
bility of these reported findings to the clinical situation of adult 
wound healing. 
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Figure 1. Collagen lattice contraction is dependent on cell and serum con-
centration. A) 1 X 10' (0), 2 X 10' (.&), 5 X 10' (0),1 X 105 ~ cellS/ill!' 
B) 2.5% (.&) , 5% (0), 10% (.) calf serum. Each POillt represents the average 
diameter of two replicate gels ± SEM. 
The mechanism by which pentoxifylline and the interferons in-
hibit FPCL contraction remains to be determ.ined but may relate to 
their previously demonstrated metabolic effects on extracellular 
matrix component production by monolayer-cultured dermal fi-
broblasts [5,24). For example, an increase in collagenase production, 
as is seen with dermal fibrobl as ts in response to interferons [5J and, 
with some strains, pentoxifylline [24,26) , may degrade the coll agen 
matrix surrounding the fibroblasts, decreasing the fibroblasts ' abil-
ity to reorganize collagen fibers and induce lattice contraction. In 
addition, a pentoxifylline- or interferon-induced decrease in fibro-
nectin production may inhibit lattice contraction because produc-
tion of cellular fibronectin is necessary for lattice contraction to 
occur [19] . Similarly, a decrease in glycosaminoglycan production 
may reduce lattice contraction because certain glycosaminoglycans, 
such as hyaluronic acid, have been shown to facilitate lattice con-
traction [18]. Furthermore, studies using other methyxanthines 
could help pinpoint structural features specific to pentoxifylline 
that may be responsible for its activity. 
Inhibition of FPCL contraction by pentoxifylline and the inter-
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Figure 2. Dose-dependent inhibition of lattice contraction by pentoxifyl-
line at 0 (.), 0.25 (0) , 0.5 (.&), and 1 (0) mg/ml. Each poillt represents the 
average diameter of three replicate gels ± SEM. 
ferons was not due to decreases in cell number or viability. Although 
pentoxifylline and the interferons have been reported to inhibit 
fibroblast proliferation in monolayer cultures [24,27]' this effect 
was not observed in the current study . This is not surprising because 
other studies have shown that fibroblast proliferation in collagen 
lattices, in contrast to monolayer culture, is unaffected by growth 
stimulators, such as platelet-derived growth factor [8,28] and epi-
dermal growth factor [29]. As opposed to the rapid proliferation of 
fibroblasts cultured in monolayers, fibroblasts cultured in collagen 
lattices proliferate slowly, if at all [4,30], and thus behave more like 
those if, vivo. 
The results from this study support the suggestion of previous 
work [5] that interferons may have a role in terminating the wound-
healing process in vivo. Following tissue damage, cells associated 
with the inflammatory response, such as neutrophils and mono-
cytes, as well as activated platelets, release growth factors and other 
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Figure 3. Dose-dependent inhibition of lattice contraction by IFN-a at 0 
(II), 1 X 102 (0), 1 X 103 (.&), 1 X 10' (0), and 1 X lOs (e) U/m!. Each 
point represents the average diameter of three replicate gels ± SEM. 
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Figure 4. Dose-dependent inhibition of lattice contraction by IFN-P at 0 
~, 10 (0), 1 X 102 (.&),1 X 103 (0),1 X 10' (e), and 1 X lOs (6) Vim!' 
Each poillt represents the average diameter of three replicate gels ± SEM. 
cytokines that stimulate fibroblast secretion of collagen and fibro-
neetin and stimulate fibroblast contraction of the wound [31,32] . 
Platelet-derived growth factor and transforming growth factor-p 
are two examples of fibroblast-activating cytokines, believed to play 
a role in the initial stages of the wound-healing process, that stimu-
late FPCL contraction [7,8]. It is likely that during the latter stages 
of wound healing there is a mechanism for inactivating fibroblasts 
and inhibiting fibroblast-mediated contraction. Little attention has 
been paid to this subject; however, the anti-fibrotic effects of the 
IFNs described by Duncan [5], and anti-contraction effects of these 
cytokines described in the current study, strongly suggest that inter-
ferons may be responsible for the necessary down-regulation of 
fibroblasts once wound healing is complete. Hence, the interferons 
may function as in vivo inhibitors of wound contraction and, along 
with pentoxifylline, may be useful as pharmacologic agents to in-
hibit wound contraction when clinically indicated. 
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Figure 5. Dose-dependent inhibition of lattice contraction by IFN-y at 0 
~, 1 X 102 (0), 1 X 103 (.&), and 1 X 10' (0) U 1m!. Each poillt represents 
the average diameter of three replicate gels ± SEM. 
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